Dual Carbonic Anhydrase and Cyclooxygenase-2 Inhibition

Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications

Volumn , Issue , 2009, Pages 255-272

  Dogné, Jean Michel ^a   Thiry, Anne ^a   Masereel, Bernard ^a   Supuran, Claudiu T ^b  

^a UNIVERSITY OF NAMUR   (Belgium)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cyclooxygenase inhibition and cardiovascular risks; Dual carbonic anhydrase and cyclooxygenase 2 inhibition; Nanomolar affinity of sulfonamide COX 2 inhibitors celecoxib and valdecoxib for CA II

Indexed keywords

EID: 77958016222     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470508169.ch11     Document Type: Chapter

References (67)

1. Roos, K. L.; Simmons, D. L. Cyclooxygenase variants: the role of alternative splicing. Biochem. Biophys. Res. Commun. 2005, 338, 62-69.
2. de Leval, X.; Julemont, F.; Benoit, V.; Frederich, M.; Pirotte, B.; Dogné, J.-M. First and second generations of COX-2 selective inhibitors. Mini Rev. Med. Chem. 2004, 4, 597-601.
3. Dogné, J.-M.; Supuran, C. T.; Pratico, D. Adverse cardiovascular effects of the coxibs. J. Med. Chem. 2005, 48, 2251-2257.
4. FitzGerald, G. A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2003, 2, 879-890.
5. Antman, E. M.; DeMets, D.; Loscalzo, J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005, 111, 759-770.
6. FitzGerald, G. A.; Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 2001, 345, 433-442.
7. Cipollone, F.; Fazia, M. L. Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular risk. Curr. Atheroscler. Rep. 2006, 8, 245-251.
8. Harris, R. E.; Beebe-Donk, J.; Alshafie, G. A. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell. Biochem. 2007, 42, 193-211.
9. Minghetti, L. Role of COX-2 in inflammatory and degenerative brain diseases. Subcell. Biochem. 2007, 42, 117-141.
10. Chandrasekharan, N. V.; Dai, H.; Roos, K. L.; Evanson, N. K.; Tomsik, J.; Elton, T. S.; Simmons, D. L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA 2002, 99, 13926-13931.
11. Qin, N.; Zhang, S. P.; Reitz, T. L.; Mei, J. M.; Flores, C. M. Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention. J. Pharmacol. Exp. Ther. 2005, 315, 1198-1305.
12. Hinz, B.; Brune, K. Antipyretic analgesics: nonsteroidal antiinflammatory drugs, selective COX-2 inhibitors, paracetamol and pyrazolinones. Handb. Exp. Pharmacol. 2007, 177, 65-93.
13. Hinz, B.; Cheremina, O.; Brune, K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 2008, 22, 383-390.
14. Huang, J. Q.; Sridhar, S.; Hunt, R. H. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002, 359, 14-22.
15. Pratico, D.; Dogné, J.-M. Selective cyclooxygenase-2 inhibitors development in cardiovascular medicine. Circulation 2005, 111, 1073-1079.
16. Garcia-Nieto, R.; Perez, C.; Checa, A.; Gago, F. Molecular model of the interaction between nimesulide and human cyclooxygenase-2. Rheumatology (Oxford) 1999, 38 (Suppl. 1), 14-18.
17. Gimbrone, M. A., Jr.; Topper, J. N.; Nagel, T.; Anderson, K. R.; Garcia-Cardena, G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann. N. Y. Acad. Sci. 2000, 902, 230-239, discussion 239-240.
18. McAdam, B.F.;Catella-Lawson,F.;Mardini, I. A.;Kapoor, S.;Lawson, J. A.; FitzGerald, G. A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA 1999, 96, 272-277.
19. Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; Dube, D.; Ethier, D.; Falgueyret, J. P.; Friesen, R.W.; Gordon, R.; Greig, G.; Guay, J.; Mancini, J.; Ouellet, M.Wong E.; Xu, L.; Boyce, S.; Visco, D.; Girard, Y.; Prasit, P.; Zamboni, R.; Rodger, I. W.; Gresser, M.; Ford-Hutchinson, A. W.; Young, R. N.; Chan, C. C. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 2001, 296, 558-566.
20. Stichtenoth, D. O.; Frolich, J. C. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 2003, 63, 33-45.
21. Bombardier, C.; Laine, L.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M. B.; Hawkey, C. J.;Hochberg,M. C.;Kvien, T.K.; Schnitzer, T. J.;Weaver, A. Response to expression of concern regarding VIGOR study. N. Engl. J.Med. 2006, 354, 1196-1199.
22. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M. B.; Hawkey, C. J.; Hochberg, M. C.; Kvien, T. K.; Schnitzer, T. J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000, 343, 1520-1528.
23. Bresalier, R. S.; Sandler, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.;Konstam, M. A.; Baron, J. A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005, 352, 1092-1102.
24. Silverstein, F. E.; Faich, G.; Goldstein, J. L.; Simon, L. S.; Pincus,T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N. M.; Stenson, W. F.; Burr, A. M.; Zhao, W. W.; Kent, J. D.; Lefkowith, J. B.; Verburg, K. M.; Geis, G. S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284, 1147-1155.
25. Schnitzer, T. J.; Burmester, G. R.; Mysler, E.; Hochberg, M. C.; Doherty, M.; Ehrsam, E.; Gitton, X.; Krammer, G.; Mellein, B.; Matchaba, P.; Gimona, A.; Hawkey, C. J. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004, 364, 665-674.
26. Krum, H.; Aw, T. J.; Liew, D.; Haas, S. Blood pressure effects of COX-2 inhibitors. J. Cardiovasc. Pharmacol. 2006, 47, (Suppl. 1), S43-S48.
27. Dogné, J.-M.; Thiry, A.; Pratico, D.; Masereel, B.; Supuran, C.T. Dual carbonic anhydrase:cyclooxygenase-2 inhibitors. Curr. Top. Med. Chem. 2007, 7, 885-891.
28. Supuran, C. T.; Casini, A.; Mastrolorenzo, A.; Scozzafava, A. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini Rev. Med. Chem. 2004, 4, 625-632.
29. Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev. 2003, 23, 146-189.
30. Abbate, F.; Supuran, C.T.; Scozzafava, A.; Orioli, P.; Stubbs, M. T.; Klebe, G. Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: role of hydrogen-bonding networks in ligand binding and drug design. J. Med. Chem. 2002, 45, 3583-3587.
31. Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C. T.; Scozzafava, A.; Klebe, G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib:new pharmacological opportunities due to related binding site recognition. J. Med. Chem. 2004, 47, 550-557.
32. Katagiri, M.; Ogasawara, T.; Hoshi, K.; Chikazu, D.; Kimoto, A.; Noguchi, M.; Sasamata, M.; Harada, S.; Akama, H.;Tazaki, H.; Chung, U. I.; Takato, T.; Nakamura, K.;Kawaguchi, H. Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II. J. Bone Miner. Res. 2006, 21, 219-227.
33. Di Fiore, A.; Pedone, C.; D'Ambrosio, K.; Scozzafava, A.; De Simone, G.; Supuran, C. T. Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II ''selective'' inhibitor celecoxib. Bioorg. Med. Chem. Lett. 2006, 16, 437-442.
34. Menchise, V.; De Simone, G.; Alterio, V.; Di Fiore, A.; Pedone, C.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membraneimpermeant antitumor sulfonamide complexed with isozyme II. J. Med. Chem. 2005, 48, 5721-5727.
35. Whelton, A.; Fort, J. G.; Puma, J. A.; Normandin, D.; Bello, A. E.; Verburg, K. M. Cyclooxygenase-2: specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther. 2001, 8, 85-95.
36. Whelton, A. Cyclooxygenase-2 inhibition and renal function. Ann. Intern. Med. 2001, 134, 1077-1078.
37. Whelton, A.COX-2-specific inhibitors and the kidney: effect on hypertension and oedema. J. Hypertens. Suppl. 2002, 20, S31-S35.
38. Whelton, A.; White, W. B.; Bello, A. E.; Puma, J. A.; Fort, J. G. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or 1/465 years of age with systemic hypertension and osteoarthritis. Am. J. Cardiol. 2002, 90, 959-963.
39. Alper,A. B., Jr.; Tomlin, H.; Sadhwani, U.; Whelton, A.; Puschett, J. Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial. Am. J. Ther. 2006, 13, 229-235.
40. Aw, T. J.; Liew, D.; Tofler,G. H.; Schneider,H. G.; Morel-Kopp, M. C.; Billah, B.; Krum, H. Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels? J. Hypertens. 2006, 24, 1979-1984.
41. Julemont, F.; de Leval, X.; Michaux, C.; Renard, J. F.;Winum, J.Y.; Montero, J. L.; Damas, J.; Dogné, J.-M.; Pirotte, B. Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. J. Med. Chem. 2004, 47, 6749-6759.
42. Waskewich, C.; Blumenthal, R. D.; Li, H.; Stein, R.; Goldenberg, D. M.; Burton, J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 2002, 62, 2029-2033.
43. Pastoreková, S.; Pastorek, J. Cancer-related carbonic anhydrase isozymes and their inhibition. Carbonic Anhydrase: Its Inhibitors and Activators; CRC Press: London, 2004; pp 255-281.
44. Stubbs, M.; McSheehy, P. M.; Griffiths, J. R.; Bashford, C. L. Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today 2000, 6, 15-19.
45. Gut, M. O.; Parkkila, S.; Vernerova, Z.; Rohde, E.; Zavada, J.; Hocker, M.; Pastorek, J.; Karttunen, T.; Gibadulinova, A.; Zavadova, Z.; Knobeloch, K. P.; Wiedenmann, B.; Svoboda, J.; Horak, I.; Pastorekova, S. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 2002, 113, 1889-1903.
46. Bartosova, M.; Parkkila, S.; Pohlodek, K.; Karttunen, T. J.; Galbavy, S.; Mucha, V.; Harris, A. L.; Pastorek, J.; Pastorekova, S. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J. Pathol. 2002, 197, 314-321.
47. Ivanov, S.; Liao, S. Y.; Ivanova, A.; Danilkovitch-Miagkova, A.; Tarasova, N.;Weirich, G.; Merrill, M. J.; Proescholdt, M. A.; Oldfield, E. H.; Lee, J.; Zavada, J.; Waheed, A.; Sly, W.; Lerman, M. I.; Stanbridge, E. J. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 2001, 158, 905-919.
48. Saarnio, J.; Parkkila, S.; Parkkila, A. K.; Pastorekova, S.; Haukipuro, K.; Pastorek, J.; Juvonen, T.; Karttunen, T. J. Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours. J. Hepatol. 2001, 35, 643-649.
49. Kivela, A. J.; Parkkila, S.; Saarnio, J.; Karttunen, T. J.; Kivela, J.; Parkkila, A. K.; Pastorekova, S.; Pastorek, J.; Waheed, A.; Sly, W. S.; Rajaniemi, H. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem. Cell Biol. 2000, 114, 197-204.
50. Vermylen, P.; Roufosse, C.; Burny, A.; Verhest, A.; Bosschaerts, T.; Pastorekova, S.; Ninane, V.; Sculier, J. P. Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. Eur. Respir. J. 1999, 14, 806-811.
51. Saarnio, J.; Parkkila, S.; Parkkila, A. K.; Haukipuro, K.; Pastorekova, S.; Pastorek, J.; Kairaluoma,M. I.; Karttunen, T. J. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am. J. Pathol. 1998, 153, 279-285.
52. McKiernan, J. M.; Buttyan, R.; Bander, N. H.; Stifelman, M. D.; Katz, A. E.; Chen, M.W.; Olsson, C. A.; Sawczuk, I. S. Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res. 1997, 57, 2362-2365.
53. Turner, J. R.; Odze, R. D.; Crum, C. P.; Resnick, M. B. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancerassociated biomarker. Hum. Pathol. 1997, 28, 740-744.
54. Liao, S. Y.; Aurelio, O. N.; Jan, K.; Zavada, J.; Stanbridge, E. J. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 1997, 57, 2827-2831.
55. Wykoff, C. C.; Beasley, N. J.;Watson, P. H.; Turner, K. J.; Pastorek, J.; Sibtain, A.Wilson G. D.; Turley, H.; Talks, K. L.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J.; Harris, A. L. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60, 7075-7083.
56. Hockel, M.; Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93, 266-276.
57. Zhou, J.; Schmid, T.; Schnitzer, S.; Brune, B. Tumor hypoxia and cancer progression. Cancer Lett. 2005, 237, 10-21.
58. Loncaster, J. A.; Harris, A. L.; Davidson, S. E.; Logue, J. P.; Hunter, R. D.;Wycoff, C. C.; Pastorek, J.; Ratcliffe, P. J.; Stratford, I. J.; West, C. M. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001, 61, 6394-6399.
59. Ivanov, S. V.; Kuzmin, I.;Wei, M. H.; Pack, S.; Geil, L.; Johnson, B. E.; Stanbridge, E. J.; Lerman, M. I. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. USA 1998, 95, 11596-11601.
60. Supuran, C. T.; Briganti, F.; Tilli, S.; Chegwidden, W. R.; Scozzafava, A. Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? Bioorg. Med. Chem. 2001, 9, 703-714.
61. Vullo, D.; Innocenti, A.; Nishimori, I.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides: a new target for the design of antitumor and antiglaucoma drugs? Bioorg. Med. Chem. Lett. 2005, 15, 963-969.
62. Xiang,Y.; Ma, B.; Li, T.; Gao, J.W.;Yu, H. M.; Li, X. J. Acetazolamide inhibits aquaporin-1 protein expression and angiogenesis. Acta Pharmacol. Sin. 2004, 25, 811-816.
63. Vukovic,V.; Tannock, I. F. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br. J. Cancer 1997, 75, 1167-1172.
64. Thiry, A.; Dogné, J.-M.; Masereel, B.; Supuran, C. T. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol. Sci. 2006, 27, 566-573.
65. Thiry, A.; Supuran, C. T.; Masereel, B.; Dogné, J.-M. Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J. Med. Chem. 2008, 51, 3051-3056.
66. Winum, J.-Y.; Rami, M.; Scozzafava, A.; Montero, J. L.; Supuran, C. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med. Res. Rev. 2008, 28, 445-463.
67. Vullo, D.; Franchi, M.; Gallori, E.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2003, 13, 1005-1009.